EGFR and non-small cell lung carcinoma: Non-invasive CDx assays (e.g., cobas EGFR Mutation Test v2, FoundationOne Liquid CDx, Guardant360 CDx) of ctDNA have been approved for certain NSCLC biomarkers (182).